Serum apolipoprotein A1: a predictor and prognostic biomarker in acute ischemic stroke

Eldeeb, Mai; Zaki, Amr S.; Ashour, Samia; Nasser, Azza Abdel; Bassiouny, Ahmed El; Abdulghani, Khaled O.

doi:10.1186/s41983-019-0138-z

Cited by 6 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apolipoprotein A1 (APOA1) is a major protein component of the high-density lipoprotein (HDL) and exhibits anti-inflammatory and antioxidant effects, hence playing an important role in the protection of the vascular system against oxidative stress. Studies have shown that the levels of APOA1 decrease in patients with stroke and/or infection [ 30 ]. Similarly, decreased levels of APOA1-UP, as a novel biomarker have been reported to have a high sensitivity (91%) and specificity (97%) for the prediction of IS, nominating it as a promising independent predictor of IS [ 16 ].…”

Section: Resultsmentioning

confidence: 99%

Blood Biomarkers for Triaging Patients for Suspected Stroke: Every Minute Counts

Jadav

Mortazavi

Yee

2022

JCM

View full text Add to dashboard Cite

Early stroke diagnosis remains a big challenge in healthcare partly due to the lack of reliable diagnostic blood biomarkers, which in turn leads to increased rates of mortality and disability. Current screening methods are optimised to identify patients with a high risk of cardio-vascular disease, especially among the elderly. However, in young adults and children, these methods suffer low sensitivity and specificity and contribute to further delays in their triage and diagnosis. Accordingly, there is an urgent need to develop reliable blood biomarkers for triaging patients suspected of stroke in all age groups, especially children and young adults. This review explores some of the existing blood biomarkers, as single biomarkers or biomarker panels, and examines their sensitivity and specificity for predicting stroke. A review was performed on PubMed and Web of Science for journal articles published in English during the period 2001 to 2021, which contained information regarding biomarkers of stroke. In this review article, we provide comparative information on the availability, clinical usefulness, and time-window periods of seven single blood biomarkers and five biomarker panels that have been used for predicting stroke in emergency situations. The outcomes of this review can be used in future research for developing more effective stroke biomarkers.

show abstract

Section: Resultsmentioning

confidence: 99%

Blood Biomarkers for Triaging Patients for Suspected Stroke: Every Minute Counts

Jadav

Mortazavi

Yee

2022

JCM

View full text Add to dashboard Cite

show abstract

“…Apolipoprotein A1 (ApoA1) is a protein component of high-density lipoprotein (HDL) and is involved in the transfer of excessive cholesterol from peripheral cells to the liver. Aside from its atheroprotective properties, apoA1 also contains anti-inflammatory and antioxidant properties (53). A previous study found that low amounts of apolipoprotein A1 and high amounts of apolipoprotein B were associated with an increased risk of cerebrovascular stroke and cardiovascular diseases (53)(54)(55)(56).…”

Section: Discussionmentioning

confidence: 99%

“…Aside from its atheroprotective properties, apoA1 also contains anti-inflammatory and antioxidant properties (53). A previous study found that low amounts of apolipoprotein A1 and high amounts of apolipoprotein B were associated with an increased risk of cerebrovascular stroke and cardiovascular diseases (53)(54)(55)(56). High levels of high-density lipoprotein (HDL) cholesterol significantly reduce the risk of stroke (57).…”

Section: Discussionmentioning

confidence: 99%

Identification of the putative causal risk factors and biomarkers of stroke using large-scale genome-wide studies

Islam

García-Marín

Rentería

et al. 2023

Preprint

View full text Add to dashboard Cite

Stroke is the second leading cause of death and the third leading cause of long-term disability in the world. This study aimed to explore the novel putative causal genetic relationship of stroke with hundreds of complex traits by leveraging genetic data. We used genome-wide association studies (GWAS) data and the latent causal variable method to identify potential causal relationships between stroke and 1,504 complex traits of the UK biobank. We found that 262 traits were genetically correlated with stroke risk at a false discovery rate (FDR <0.05). Of those correlated traits, 28 showed robust evidence of partial genetic causality (GCP) with stroke (|GCP|> 0.60; FDR < 0.05). Our results showed that some conditions, including atrial fibrillation, pulmonary embolism, blood clots in the lung, platelet crit, self-reported deep venous thrombosis, weight gain after depression, and the use of some medications such as insulin, pioglitazone, and gliclazide were inferred to increase stroke risk. On the other hand, greater levels of testosterone, apolipoprotein A, SHBG, and HDL cholesterol decrease the risk of stroke. Also, our results suggest that genetic susceptibility to stroke raises the risk of neck and chest pain and loose teeth. Finally, our findings suggest that cardiac vascular disease, blood clot in lung, deep venous thrombosis, and certain anti-diabetic medications could have a causal role in increasing the risk of stroke, which could be used as novel testable hypotheses for future epidemiological studies.

show abstract

“…Furthermore, APOA-1 functions as an antioxidant and an anti-inflammatory (Georgila, Vyrla, & Drakos, 2019). APOA-1-related studies have illustrated that APOA-1 levels can be employed as a predictor and prognostic tool in ischemic stroke patients (Eldeeb et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Single Nucleotide Variation in the Promoter Region of the APOA1 Gene as a Candidate Biomarker for Dyslipidemia

Rahajoe,

Nugraheni,

Pinda Ayu Widiyani

et al. 2023

j. info kesehat.

View full text Add to dashboard Cite

Dyslipidemia is a lipid profile abnormality that can escalate the risk of cardiovascular disease. The rate of cardiovascular events in Indonesia is very high. One of the causes of dyslipidemia is due to polymorphisms in genes associated with lipid metabolism. The APOA-1 gene encodes the APOA-1 protein which functions to regulate HDL protein synthesis. The objective of this study is to determine APOA1 gene polymorphisms in patients with dyslipidemia. Samples of healthy controls and dyslipidemia patients were used in this investigation. The lipid profiles of the patients and normal controls are determined at the onset of the study. Following DNA extraction, the APOA-1 gene was amplified and sequenced using the serum sample. MEGA X and BLAST were used to analyze the sequencing results. The study's findings demonstrated that the APOA-1 gene length in samples of dyslipidemic patients and normal controls was 433 bp. While the normal control samples have the same sequence as the database, the dyslipidemic patient samples have an APOA-1 gene polymorphism in the promoter region. APOA-1 gene polymorphism results in disturbances in lipid profiles, particularly HDL which is at risk of developing dyslipidemia. The APOA-1 gene has the potential to be developed as a biomarker for diagnosing dyslipidemia involving a larger number of samples.

show abstract

Serum apolipoprotein A1: a predictor and prognostic biomarker in acute ischemic stroke

Cited by 6 publications

References 15 publications

Blood Biomarkers for Triaging Patients for Suspected Stroke: Every Minute Counts

Blood Biomarkers for Triaging Patients for Suspected Stroke: Every Minute Counts

Identification of the putative causal risk factors and biomarkers of stroke using large-scale genome-wide studies

Single Nucleotide Variation in the Promoter Region of the APOA1 Gene as a Candidate Biomarker for Dyslipidemia

Contact Info

Product

Resources

About